(Q35173016)

6 August 2017

1 reference

title

Antibody-targeted chemotherapy of acute myeloid leukemia using gemtuzumab ozogamicin (Mylotarg). (English)

1 reference

6 August 2017

1 reference

acute myeloid leukemia

1 reference

Eric L Sievers

1

1 reference

6 August 2017

publication date

1 July 2003

1 reference

Blood Cells, Molecules and Diseases

6 August 2017

published in

1 reference

6 August 2017

volume

31

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

7-10

1 reference

Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1079-9796%2803%2900117-7

7 January 2021

A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide

1 reference

https://api.crossref.org/works/10.1016%2FS1079-9796%2803%2900117-7

7 January 2021

The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1079-9796%2803%2900117-7

7 January 2021

Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis

1 reference

https://api.crossref.org/works/10.1016%2FS1079-9796%2803%2900117-7

7 January 2021

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1016%2FS1079-9796%2803%2900117-7

7 January 2021

Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1079-9796%2803%2900117-7

7 January 2021

10.1016/S1079-9796(03)00117-7

Identifiers

DOI

1 reference

6 August 2017

1 reference